Bicara Therapeutics
BCAX
16.00
-0.42
-2.56%
Bicara Therapeutics
US · BCAX
#3193 by market cap
Listed 2024
16.00
-0.42
-2.56%
Live - 5344 symbols - heartbeat 482s ago
· 2026-10-08 10:00
Pre-market
16.68
+1.58%
After-hours
16.42
0.00%
- Market cap
- 1.06B
- P/E (TTM)i
- -5.21
- P/Bi
- 2.26
- EPSi
- -2.52
- Div yieldi
- 0.00%
- 52W posi
- 13%
Reader sentiment
Are you bullish or bearish on BCAX?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 4 years
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 6.34M | 9.27M | 18.77M | 30.51M |
| Research & development | 31.31M | 30.62M | 63.62M | 125.10M |
| Operating profit | -37.66M | -39.89M | -82.39M | -155.60M |
| Pretax profit | -37.84M | -51.98M | -67.81M | -137.73M |
| Tax | 1.00K | 5.00K | 187.00K | 217.00K |
| Net profit | -37.85M | -51.99M | -68.00M | -137.95M |
| Basic EPS | -2 | -2 | -4 | -3 |
| Diluted EPS | -2.45 | -1.53 | -4.05 | -2.52 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 7.46M | 7.22M | 7.70M | 8.13M | 12.74M | 14.18M |
| Research & development | 34.33M | 24.80M | 32.98M | 32.99M | 47.50M | 45.77M |
| Operating profit | -41.79M | -32.02M | -40.68M | -41.12M | -60.24M | -59.95M |
| Pretax profit | -36.77M | -27.34M | -36.29M | -37.33M | -56.16M | -55.38M |
| Tax | 72.00K | 52.00K | 40.00K | 53.00K | 52.00K | 61.00K |
| Net profit | -36.85M | -27.39M | -36.33M | -37.39M | -56.21M | -55.44M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.68 | -0.50 | -0.67 | -0.68 | -0.93 | -0.82 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 4.98M | 231.07M | 502.53M | 422.05M |
| Cash & ST investments | 4.16M | 230.44M | 489.71M | 414.80M |
| Inventory | -- | -- | -- | -- |
| Total assets | 6.70M | 233.98M | 510.00M | 430.99M |
| Total current liabilities | 23.90M | 15.09M | 17.99M | 28.95M |
| Short-term debt | -- | 285.00K | 607.00K | 1.12M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | 105,506,000.00 | 382,751,000.00 | 18,121,000.00 | 29,542,000.00 |
| Total equity | -98.80M | -148.77M | 491.88M | 401.45M |
| Retained earnings | -101.04M | -153.02M | -221.02M | -358.97M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 470.75M | 444.39M | 297.37M | 422.05M | 544.92M | 503.82M |
| Cash & ST investments | 462.07M | 436.61M | 290.17M | 414.80M | 539.75M | 497.26M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 478.08M | 453.59M | 424.69M | 430.99M | 553.60M | 512.24M |
| Total current liabilities | 19.12M | 17.23M | 21.03M | 28.95M | 39.34M | 43.48M |
| Short-term debt | 591.00K | 1.07M | 1.10M | 1.12M | 1.14M | 1.16M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 19,120,000.00 | 18,391,000.00 | 21,908,000.00 | 29,542,000.00 | 39,641,000.00 | 43,475,000.00 |
| Total equity | 458.96M | 435.20M | 402.78M | 401.45M | 513.96M | 468.77M |
| Retained earnings | -257.86M | -285.25M | -321.58M | -358.97M | -415.18M | -470.61M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -32.08M | -45.63M | -74.75M | -106.83M |
| Depreciation & amortization | 10.00K | 19.00K | 56.00K | 105.00K |
| Free cash flow | -32.27M | -46.21M | -74.82M | -107.11M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 332.43M | 29.50M |
| Ending cash balance | 4.16M | 230.44M | 489.71M | 96.69M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -28.11M | -25.59M | -29.25M | -23.89M | -37.51M | -44.21M |
| Depreciation & amortization | 19.00K | 19.00K | 24.00K | 43.00K | 44.00K | 44.00K |
| Free cash flow | -28.11M | -25.59M | -29.29M | -24.12M | -37.57M | -44.27M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 29.50M | 161.76M | 0 |
| Ending cash balance | 462.07M | 436.61M | 171.67M | 96.69M | 323.46M | 96.60M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -39.64 | -30.88 |
| ROA %i | -564.60 | -43.20 | -18.28 | -29.32 |
| ROIC %i | -- | -- | -47.94 | -33.95 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | 0.21 | 15.32 | 27.93 | 14.58 |
| Quick ratioi | 0.17 | 15.28 | 27.22 | 14.33 |
| Debt / assetsi | 0.00 | 0.28 | 0.14 | 0.40 |
| LT debt / equityi | -- | -- | 0.03 | 0.15 |
| Interest coveragei | -336.89 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -20.12 | -78.85 | -26.64 | -30.88 | -32.34 | -41.01 |
| ROA %i | -19.31 | -31.00 | -25.61 | -29.32 | -30.50 | -38.38 |
| ROIC %i | -22.97 | -89.26 | -30.01 | -33.95 | -34.36 | -43.08 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 24.62 | 25.80 | 14.14 | 14.58 | 13.85 | 11.59 |
| Quick ratioi | 24.17 | 25.34 | 13.80 | 14.33 | 13.72 | 11.44 |
| Debt / assetsi | 0.12 | 0.49 | 0.47 | 0.40 | 0.26 | 0.23 |
| LT debt / equityi | -- | 0.27 | 0.22 | 0.15 | 0.06 | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 10:00:10 · For reference only, not investment advice and not tailored to your situation.